---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-254135"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:42:18.823636+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma to present updated Phase 1 PC14586 data at AACR-NCI-EORTC; KOL webinar planned

## Summary
- Updated Phase 1 data cutoff Sep 5, 2023; abstract with May 1 cutoff published.
- Poster session October 12, 2023 12:30-4:00 PM ET at AACR-NCI-EORTC conference.
- PC14586 targets p53 Y220C mutation in advanced solid tumors; PYNNACLE study ongoing.
- KOL webinar October 12 at 4:00 PM ET with regulatory update included.
- Data also discussed in Chemistry in Cancer Research Town Hall and Concurrent Session 8.

## SEC filing metadata
- accession: 0001193125-23-254135
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312523254135/0001193125-23-254135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312523254135/d516537d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-254135
- JSON: https://secwatch.observer/filing/0001193125-23-254135.json
- Plain text: https://secwatch.observer/filing/0001193125-23-254135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.